Page last updated: 2024-10-16

adenine and Thrombopenia

adenine has been researched along with Thrombopenia in 16 studies

Research Excerpts

ExcerptRelevanceReference
"A 56-year-old male patient received adefovir dipivoxil (10 mg/day) for chronic hepatitis B resistant to lamivudine."7.73Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B. ( Amato, A; Gaeta, GB; Stornaiuolo, G, 2006)
"A 56-year-old male patient received adefovir dipivoxil (10 mg/day) for chronic hepatitis B resistant to lamivudine."3.73Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B. ( Amato, A; Gaeta, GB; Stornaiuolo, G, 2006)
"After minimal residual disease-guided treatment (day 1 of month 16), 84 (62%, 90% CI 55-69) of 135 patients (ITT population) achieved a complete response with bone marrow minimal residual disease of less than 0·01%."2.90Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. ( Aanei, C; Aurran, T; Banos, A; Carassou, P; Cartron, G; Cymbalista, F; Dartigeas, C; de Guibert, S; Delmer, A; Dilhuydy, MS; Feugier, P; Fornecker, LM; Laribi, K; Le Garff-Tavernier, M; Leblond, V; Lepretre, S; Letestu, R; Lévy, V; Mahe, B; Michallet, AS; Nguyen-Khac, F; Orsini, F; Pegourie, B; Portois, C; Rouille, V; Salles, G; Subtil, F; Ticchioni, M; Tomowiak, C; Tournilhac, O; Truchan Graczyk, M; Villemagne, B; Vilque, JP; Ysebaert, L, 2019)
"Between Sept 19, 2012, and Jan 21, 2014, 578 eligible patients were randomly assigned to ibrutinib or placebo in combination with bendamustine plus rituximab (289 in each group)."2.82Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. ( Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mato, A; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D, 2016)
"Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration."2.53[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. ( Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S, 2016)
"Familial macrothrombocytopenias are a group of rare autosomal dominant platelet disorders including many syndromes in particular the May-Hegglin anomaly."1.33[The MYH9 syndrome: report of a new case with a new mutation of the MYH9 gene]. ( Bardet, V; Berda-Haddad, Y; Bernit, E; Camoin, L; Difeo, A; Ebbo, M; Favier, R; Harle, JR; Heudier, P; Kaplanski, G; Mazodier, K; Schleinitz, N; Veit, V, 2006)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19904 (25.00)18.7374
1990's2 (12.50)18.2507
2000's2 (12.50)29.6817
2010's6 (37.50)24.3611
2020's2 (12.50)2.80

Authors

AuthorsStudies
Wang, ML1
Jain, P1
Zhao, S1
Lee, HJ1
Nastoupil, L1
Fayad, L1
Ok, CY1
Kanagal-Shamanna, R1
Hill, HA1
Yao, Y1
Hagemeister, FB1
Westin, JR1
Fowler, N1
Samaniego, F1
Steiner, R1
Nair, R1
Iyer, SP1
Navsaria, L1
Badillo, M1
Feng, L1
Xuelin, H1
Nogueras Gonzalez, GM1
Xu, G1
Wagner-Bartak, N1
Thirumurthi, S1
Santos, D1
Tang, G1
Lin, P1
Wang, SA1
Jorgensen, J1
Yin, CC1
Li, S1
Patel, KP1
Vega, F1
Medeiros, LJ1
Flowers, CR1
Wang, L1
Rogers, KA1
Huang, Y1
Ruppert, AS1
Abruzzo, LV1
Andersen, BL1
Awan, FT1
Bhat, SA1
Dean, A1
Lucas, M1
Banks, C1
Grantier, C1
Heerema, NA1
Lozanski, G1
Maddocks, KJ1
Valentine, TR1
Weiss, DM1
Jones, JA1
Woyach, JA1
Byrd, JC1
Law, YXT1
Lee, LS1
Michallet, AS1
Dilhuydy, MS2
Subtil, F1
Rouille, V1
Mahe, B1
Laribi, K1
Villemagne, B1
Salles, G1
Tournilhac, O1
Delmer, A1
Portois, C1
Pegourie, B1
Leblond, V1
Tomowiak, C1
de Guibert, S1
Orsini, F1
Banos, A1
Carassou, P1
Cartron, G1
Fornecker, LM1
Ysebaert, L1
Dartigeas, C1
Truchan Graczyk, M1
Vilque, JP1
Aurran, T1
Cymbalista, F1
Lepretre, S1
Lévy, V1
Nguyen-Khac, F1
Le Garff-Tavernier, M1
Aanei, C1
Ticchioni, M1
Letestu, R1
Feugier, P1
Herishanu, Y1
Katz, BZ1
Chanan-Khan, A1
Cramer, P1
Demirkan, F1
Fraser, G1
Silva, RS1
Grosicki, S1
Pristupa, A1
Janssens, A1
Mayer, J2
Bartlett, NL1
Pylypenko, H1
Loscertales, J1
Avigdor, A1
Rule, S1
Villa, D1
Samoilova, O1
Panagiotidis, P1
Goy, A1
Mato, A1
Pavlovsky, MA1
Karlsson, C1
Mahler, M1
Salman, M1
Sun, S1
Phelps, C1
Balasubramanian, S1
Howes, A1
Hallek, M1
Adam, Z1
Pour, L1
Krejčí, M1
Ševčíková, S1
Pourová, E1
Ševčíková, E1
Král, Z1
Quach, H1
Lee, LY1
Smith, B1
Korman, T1
Woolley, IJ1
CANCI, A1
JOHNSON, SA1
GREENWALT, TJ1
ARNAUD, SB1
PAWLOWSKI, JM1
Stornaiuolo, G1
Amato, A1
Gaeta, GB1
Schleinitz, N1
Favier, R1
Mazodier, K1
Difeo, A1
Ebbo, M1
Veit, V1
Berda-Haddad, Y1
Bernit, E1
Heudier, P1
Kaplanski, G1
Camoin, L1
Bardet, V1
Harle, JR1
Asbury, R1
Blessing, JA1
Podczaski, E1
Ball, H1
Cowan, DH1
Graham, RC1
Hanson, KH1
Crowley, J1
Salmon, SE1
Keppen, M1
Braun, TJ1
Bonnet, JD1
Hellem, AJ1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy[NCT02427620]Phase 2131 participants (Anticipated)Interventional2015-06-03Active, not recruiting
Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)[NCT02427451]Phase 1/Phase 287 participants (Actual)Interventional2015-08-03Active, not recruiting
"Phase II, Multicenter, Trial, Exploring Chemo-free Treatment (GA101+Ibrutinib) and MRD-driven Strategy in Previously Untreated Symptomatic B-chronic Lymphocytic Leukemia Medically Fit A Study From the Goelams/GCFLLC/MW Intergroup"[NCT02666898]Phase 2135 participants (Actual)Interventional2015-10-31Completed
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic[NCT01611090]Phase 3578 participants (Actual)Interventional2012-09-19Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT)

Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported. (NCT01611090)
Timeframe: Baseline to EOT (Up to 2 years)

Interventionmilligram per liter (mg/L) (Mean)
Ibrutinib+BR-0.46
Placebo+BR-0.23

Change From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment

"EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from 1 = not at all to 4 = very much. Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from 1 = very poor to 7 = excellent. Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms." (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR-2.1
Placebo+BR-4.1

Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment

The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility. (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR0.0
Placebo+BR0.0

Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment

The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR-4.3
Placebo+BR4.0

Change From Baseline in FACIT-Fatigue Scale at End of Treatment

FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR-0.9
Placebo+BR0.0

Median Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale

Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Up to 2 years

InterventionMonths (Number)
Ibrutinib+BR6.5
Placebo+BR4.6

Number of Participants Who Received Subsequent Antineoplastic Therapy

Number of participants who received subsequent antineoplastic therapy was reported. (NCT01611090)
Timeframe: Up to 5 years

InterventionParticipants (Count of Participants)
Ibrutinib+BR52
Placebo+BR61

Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms

The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia. (NCT01611090)
Timeframe: From the date of randomization to disease progression (Up to 2 years)

InterventionParticipants (Count of Participants)
Ibrutinib+BR0
Placebo+BR0

Overall Response Rate (ORR)

ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils >1.5*10^9/liter (L), platelets >100*10^9/L, Hgb >11 gram per deciliter (g/dL) and absolute lymphocyte count <4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: >=50% decrease in ALC, >=50% decrease in sum products of up to 6 lymph nodes, >=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils >1.5*10^9/L, Platelets >100*10^9/L and Hgb>11 g/dL or >=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly. (NCT01611090)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Ibrutinib+BR87.2
Placebo+BR66.1

Overall Survival (OS)

OS was defined as the interval between the date of randomization and the date of death from any cause. (NCT01611090)
Timeframe: Up to 5 years

InterventionMonths (Median)
Ibrutinib+BRNA
Placebo+BRNA

Percentage of Participants With Minimal Residual Disease (MRD)-Negative Response

MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia [CLL] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders. (NCT01611090)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Ibrutinib+BR28.7
Placebo+BR5.9

Progression-free Survival (PFS)

PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); >=50% increase in existing lymph nodes; >=50% increase in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) or >=50% increase from nadir count confirmed on >=2 serial assessments if absolute lymphocyte count (ALC) >=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b [Hgb] or platelets) attributable to CLL; and transformation to a more aggressive histology. (NCT01611090)
Timeframe: Up to 5 years

InterventionMonths (Median)
Ibrutinib+BR65.12
Placebo+BR14.32

Change From Baseline in EORTC QLQ-CLL 16 Domain Scores at End of Treatment

The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

,
InterventionUnits on the scale (Mean)
Lost weightDry mouthBruisesAbdominal discomfortTemperature going up and downNight sweatsSkin problemsFeel illFeel lethargicFelt slowed downLimited in planning activitiesWorried about health in the futureTrouble with chest infectionsTrouble with other infectionsRepeated courses of antibioticsWorried about picking up infection
Ibrutinib+BR0.10.30.10.10.1-0.60.40.10.10.30.20.00.20.70.90.3
Placebo+BR0.00.10.00.00.0-0.30.30.20.00.00.10.00.00.10.00.2

Percentage of Participants With Sustained Hematologic Improvement

Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (>)100* 109/liter (L) if baseline less than or equal to (<=) 100*109/L or increase >= 50 percent (%) over baseline; 2) Hemoglobin >11 gram per deciliters (g/dL) if baseline <= 11 g/dL or increase >= 2 g/dL over baseline. (NCT01611090)
Timeframe: Up to 5 years

,
InterventionPercentage of Participants (Number)
HemoglobinPlatelets
Ibrutinib+BR36.730.8
Placebo+BR29.121.8

Reviews

2 reviews available for adenine and Thrombopenia

ArticleYear
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
    Vnitrni lekarstvi, 2016, Volume: 62, Issue:1

    Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc

2016
Metabolic disorders of platelets.
    Advances in internal medicine, 1971, Volume: 17

    Topics: Adenine; Blood Platelet Disorders; Blood Platelets; Blood Proteins; Cell Aggregation; Clofibrate; Fi

1971

Trials

6 trials available for adenine and Thrombopenia

ArticleYear
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
    The Lancet. Oncology, 2022, Volume: 23, Issue:3

    Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxoru

2022
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 11-01, Volume: 38, Issue:31

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2020
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
    The Lancet. Haematology, 2019, Volume: 6, Issue:9

    Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dr

2019
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    The Lancet. Oncology, 2016, Volume: 17, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atr

2016
A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
    American journal of clinical oncology, 1998, Volume: 21, Issue:3

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Imides; Isoquinoline

1998
Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study.
    Anti-cancer drugs, 1991, Volume: 2, Issue:3

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Blood Cell Count; Drug Resistance; Female; Granulocytes

1991

Other Studies

8 other studies available for adenine and Thrombopenia

ArticleYear
Sudden Flank Pain in a Patient Receiving Ibrutinib for Mantle Cell Lymphoma.
    JAMA oncology, 2018, Jan-01, Volume: 4, Issue:1

    Topics: Acute Disease; Adenine; Female; Flank Pain; Hematoma; Humans; Kidney Diseases; Lymphoma, Mantle-Cell

2018
Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy.
    Blood, 2015, Feb-05, Volume: 125, Issue:6

    Topics: Adenine; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochlo

2015
Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia.
    AIDS (London, England), 2012, Sep-24, Volume: 26, Issue:15

    Topics: Adenine; Benzoates; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil

2012
[Effect of adenine on thrombopenia induced by experimental benzene poisoning].
    Bollettino della Societa italiana di biologia sperimentale, 1955, Volume: 31, Issue:5

    Topics: Adenine; Benzene; Blood Platelets; Poisoning; Thrombocytopenia

1955
RELATION OF STORAGE TO THE FUNCTION AND ULTRASTRUCTURAL CHANGES OF TRANSFUSED SURVIVING HUMAN PLATELETS IN THROMBOCYTOPENIC PATIENTS.
    Bibliotheca haematologica, 1964, Volume: 19

    Topics: Adenine; Blood Cell Count; Blood Platelets; Blood Preservation; Blood Transfusion; Electrons; Humans

1964
Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2006, Volume: 38, Issue:3

    Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Thro

2006
[The MYH9 syndrome: report of a new case with a new mutation of the MYH9 gene].
    La Revue de medecine interne, 2006, Volume: 27, Issue:10

    Topics: Adenine; Adolescent; Exons; Female; Humans; Molecular Motor Proteins; Myosin Heavy Chains; Point Mut

2006
Studies on the platelet defect in alcoholism.
    Thrombosis et diathesis haemorrhagica, 1975, Apr-30, Volume: 33, Issue:2

    Topics: Adenine; Adenosine Diphosphate; Adenosine Triphosphate; Alcoholism; Autoimmune Diseases; Blood Plate

1975